Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shinpoong Pharmaceutical Co's Enterprise Value is ₩533,797 Mil.
Shinpoong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₩13,092 Mil. Therefore, Shinpoong Pharmaceutical Co's EV-to-FCF for today is 40.77.
The historical rank and industry rank for Shinpoong Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
XKRX:019170'
s EV-to-FCF Range Over the Past 10 Years
Min: -102.72 Med: 17.12 Max: 818.68
Current: 40.57
During the past 13 years, the highest EV-to-FCF of Shinpoong Pharmaceutical Co was 818.68. The lowest was -102.72. And the median was 17.12.
XKRX:019170's EV-to-FCF is ranked worse than 71.55% of 566
companies
in the Drug Manufacturers industry
Industry Median: 19.435
vs XKRX:019170: 40.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shinpoong Pharmaceutical Co (XKRX:019170) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shinpoong Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Shinpoong Pharmaceutical Co's share price for today is ₩10070.00.
Shinpoong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-13.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shinpoong Pharmaceutical Co EV-to-FCF Related Terms
Shinpoong Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shinpoong Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shinpoong Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shinpoong Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shinpoong Pharmaceutical Co's EV-to-FCF falls into.
Shinpoong Pharmaceutical Co's current Enterprise Value is ₩533,797 Mil.
Shinpoong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩13,092 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shinpoong Pharmaceutical Co (XKRX:019170) has a EV-to-FCF of 40.77 as of Sep. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shinpoong Pharmaceutical Co and its competitors. This is 138% above median its historical median of 17.12. According to the industry distribution chart, Shinpoong Pharmaceutical Co ranks #405 out of 566 companies in the Drug Manufacturers industry, placing it in the top 71.6%.
Is Shinpoong Pharmaceutical Co's EV-to-FCF too high?
Shinpoong Pharmaceutical Co's current EV-to-FCF of 40.77 is 138% above median its 10-year median of 17.12. The Drug Manufacturers industry median EV-to-FCF is 19.44. Shinpoong Pharmaceutical Co's value of 40.77 is 109.8% above this industry median. Based on the distribution chart, Shinpoong Pharmaceutical Co ranks #405 out of 566 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shinpoong Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shinpoong Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shinpoong Pharmaceutical Co ranks #405 out of 566 companies for EV-to-FCF. This places Shinpoong Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 19.44. Shinpoong Pharmaceutical Co's value of 40.77 is 109.8% above this benchmark. While the company's 10-year median is 17.12 vs. the industry median of 19.44, Shinpoong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.44, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shinpoong Pharmaceutical Co's current EV-to-FCF of 40.77 is 109.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shinpoong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shinpoong Pharmaceutical Co's current EV-to-FCF is 40.77, which is 138% above median its own 10-year median of 17.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shinpoong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co (XKRX:019170) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩11,211.69, compared to a current price of ₩10,070.00 — trading 10.2% below its estimated fair value. The current EV-to-FCF is 40.77, which is 138% above median its 10-year median of 17.12 and 109.8% above the Drug Manufacturers industry median of 19.44. Shinpoong Pharmaceutical Co's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shinpoong Pharmaceutical Co (XKRX:019170), the current EV-to-FCF is 40.77 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shinpoong Pharmaceutical Co (XKRX:019170) Overvalued in 2026?
Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ₩10,070.00 is trading 10.2% below its estimated GF Value™ of ₩11,211.69.
GuruFocus considers Shinpoong Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XKRX:019170:
EV-to-FCF: 40.77 (138% above median its 10-year median of 17.12)
GF Value™: ₩11,211.69 vs. price of ₩10,070.00 (10.2% below fair value)
Industry Position: 109.8% above the Drug Manufacturers median (#405 of 566)
No single metric tells the full story. See the XKRX:019170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.
65GF Score
Get the complete analysis for XKRX:019170
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:019170 has been successfully added to your 
